TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic ...
Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
Summit, N.J., June 29 /PRNewswire-FirstCall/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA) has granted approval for ...
FDA approved triplet therapy for relapsed/refractory LBCL, including specific subtypes, for patients ineligible for auto-HSCT or CAR T-cell therapy. The therapy includes brentuximab vedotin, ...
Andrzej Jakubowiak, MD, PhD, director of the multiple myeloma program at the University of Chicago, discusses the definitive results of the phase 3 ATLAS trial (NCT02659293), recently published in The ...
Data from a large phase III trial presented at the 2022 American Society of Hematology (ASH) annual meeting examined the relationship between minimal residual disease, progression-free survival, and ...
Dr. Reddy’s is introducing lenalidomide capsules, a generic of Revlimid. With this volume-limited launch, Dr. Reddy’s is eligible for first to market, 180 days of generic drug exclusivity for ...
Assessing out-of-pocket cost differences in treatment for Medicare-eligible patients with favorable prognosis early-stage Hodgkin lymphoma. Economic burden and healthcare resource utilization (HRU) ...
waveLINE-007: Phase 2 study of zilovertamab vedotin (ZV) in combination with cyclophosphamide, doxorubicin, and prednisone plus rituximab (R-CHP) in previously untreated diffuse large B-cell lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results